vascular tissue News
-
Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
-
SANUWAVE Announces New Board Leadership
SANUWAVE Health, Inc. (SNWV), a leading provider of next-generation wound care products, today announced three new board members will join as one departs. “We are excited to expand our board with three new members who will help us reach new heights by bringing diverse expertise and insight to our work,” said SANUWAVE CEO & Chairman of the Board Kevin A. Richardson, II. “We ...
-
SANUWAVE Health Announces Expansion of Ametus Group Distribution Partnership
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in ...
-
SANUWAVE Business Update
SANUWAVE Health, Inc. (SNWV), a leading provider of next-generation wound care products, has announced they will be updating shareholders on a monthly basis during 2022 with regards to their Sales Funnel and System Trials. This news comes simultaneously with the company’s announcement for growth through a medical non-wound care vertical market expansion. Both the Sales Funnel, defined as ...
-
SANUWAVE Rebrands to Reflect Evolved Wound Care Solutions
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
-
SANUWAVE Health and JV Partner Diversa S.A. Announce Distribution Agreement with Grupo Suprimed
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products and its JV partner Diversa S.A. have announced a new distribution agreement with Grupo Suprimed to market and sell the dermaPACE® System in the private healthcare market in Brazil. The dermaPACE® System is currently licensed or approved for advanced wound care indications in Brazil, Mexico and ...
-
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it has received notice of allowance for foundational patent applications for two of its core technologies in several key markets further strengthening the company’s intellectual ...
-
VIDA Introduces New AI-Enabled Biomarker Services
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage ...
-
Colibri Heart Valve Forms a New Entity to Monetize Tissue Processing Technology in Applications Outside of Structural Heart
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...
-
Colibri Heart Valve Forms a New Entity to Monetize Tissue Processing Technology in Applications Outside of Structural Heart
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...
-
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem Cell Drug Delivery Technology
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
-
Cryoliposculpt by Biotec Italia, the scientifically proven evolution of traditional Cryolipolysis
A valid alternative to liposuction is represented by Cryolipolysis, a non-invasive Aesthetic Medicine technique for body contouring. The Biotec Italia Medical team has patented Cryoliposculpt, an innovative device that stands out from other technologies on the market. This is a true evolution of cryolipolysis procedures, as also demonstrated by numerous scientific articles written on ...
-
SANUWAVE Health Presents dermaPACE System Treatment Study Results Showing Enhanced Localized Wound Tissue Oxygenation
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field today presented results from a clinical case series that demonstrated improved wound healing when treated with its FDA-cleared, ...
-
Marizyme Announces Approval for DuraGraft in India
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme's distribution partner Regency Lifesciences. India ...
-
SANUWAVE Health Announces Patent Activity from March 2021 to March 2022
SANUWAVE Health, Inc. (SNWV) focuses on the development and commercialization of innovative advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications of shockwave and ultrasound systems in the non-medical field, announced today the patent activity for the past year. For the shockwave technology, the following new ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you